+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells

Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells

Current Medicinal Chemistry 23(15): 1496-1512

Aberrant expression and activation of receptor tyrosine kinases (RTK) is a frequent feature of tumor cells that may underlie tumor aggressiveness. Among RTK, Axl, a member of the Tyro3-Axl-Mer family, represents a potential therapeutic target in different tumor types given its over-expression which leads to activation of oncogenic signaling promoting cell proliferation and survival, as well as migration and invasion. Axl can promote aggressiveness of various cell types through PI3K/Akt and/or MAPK/ERK, and its expression can be transcriptionally regulated by multiple factors. Deregulated Axl expression and activation have been shown to be implicated in reduced sensitivity of tumor cells to target-specific and conventional antitumor agents, but the precise mechanism underlying these phenomena are still poorly understood. Several small molecules acting as Axl inhibitors have been reported, and some of them are undergoing clinical investigation. In this review, we describe Axl biological functions, its expression in cancer and in drug-resistant tumor cells and the development of inhibitors tailored to this receptor tyrosine kinase.

(PDF emailed within 1 workday: $29.90)

Accession: 058791181

Download citation: RISBibTeXText

PMID: 27048336

Related references

Antibody targeting of the EphA2 receptor tyrosine kinase on breast cancer cells. Proceedings of the American Association for Cancer Research Annual Meeting 44: 1234, July, 2003

Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib. Cancer Management and Research 6: 397-404, 2014

Targeting receptor tyrosine kinase on lymphatic endothelial cells for the therapy of colon cancer lymph node metastasis. Neoplasia 8(9): 747-757, 2006

The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells. Molecular Cancer 10: 82-82, 2011

Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase. Cancer ChemoTherapy and Pharmacology 67(5): 1073-1083, 2011

EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors. Febs Journal 277(2): 316-326, 2010

Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics. Molecular Pharmaceutics 8(6): 2310-2319, 2012

Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer cells. Plos One 8(7): E69104-E69104, 2014

An Inducible TGF-β2-TGFβR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases. Plos One 10(5): E0123600-E0123600, 2016

Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. Bmc Medicine 10: 28-28, 2012

Targeting RET receptor tyrosine kinase activation in cancer. Clinical Cancer Research 16(24): 5936-5941, 2011

miR-27b-3p suppresses cell proliferation through targeting receptor tyrosine kinase like orphan receptor 1 in gastric cancer. Journal of Experimental & Clinical Cancer Research 34(): 139-139, 2016

Biological significance and targeting of c-Met tyrosine kinase receptor in cancer. Frontiers in Bioscience 18: 454-473, 2013

Apoptotic sensitization in non-small cell lung cancer cells through tyrosine kinase inhibition Possible role for cytokine signaling and non-receptor tyrosine kinases as regulators of caspase activation and NSCLC cell survival. Proceedings of the American Association for Cancer Research Annual Meeting 42: 131, March, 2001

Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress. Journal of Medicinal Chemistry 57(11): 4427-4453, 2014